SEC Comment Letter for Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306) (TNXP) — May 9, 2018
Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306)
Date: May 9, 2018 · CIK: 0001430306 · Accession: 0000000000-18-014442
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-224586
Letter
May 9, 2018 Seth Lederman Chief Executive Officer Tonix Pharmaceuticals Holding Corp. 509 Madison Avenue, Suite 306 New York, New York 10022 Re:Tonix Pharmaceuticals Holding Corp. Registration Statement on Form S-3 Filed May 1, 2018 File No. 333-224586 Dear Dr. Lederman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at 202-551-6553 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Steven M. Skolnick, Esq.
Show Raw Text
May 9, 2018
Seth Lederman
Chief Executive Officer
Tonix Pharmaceuticals Holding Corp.
509 Madison Avenue, Suite 306
New York, New York 10022
Re:Tonix Pharmaceuticals Holding Corp.
Registration Statement on Form S-3
Filed May 1, 2018
File No. 333-224586
Dear Dr. Lederman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Irene Paik at 202-551-6553 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Steven M. Skolnick, Esq.